In the January 17, 2025, issue of the Federal Register, the Drug Enforcement Administration and the Department of Health and Human Services published two final rules related to the practice of telemedicine, titled "Expansion of Buprenorphine Treatment via Telemedicine Encounter" and "Continuity of Care via Telemedicine for Veterans Affairs Patients." These final rules were scheduled to become final on February 18, 2025. In accordance with the Presidential Memorandum of January 20, 2025, titled "Regulatory Freeze Pending Review," the Drug Enforcement Administration and the Department of Health and Human Services are delaying the effective dates of these two final rules to March 21, 2025, and are soliciting public comments specifically regarding this delayed effective date.
US Federal Register - DEA Telehealth Rules · February 19, 2025
Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients — Effective Date Delayed to March 21, 2025
Original title: Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
DEA and HHS delayed the effective date of two final rules expanding buprenorphine telemedicine treatment and VA continuity of care via telemedicine from February 18 to March 21, 2025, pending regulatory review.
Applies from
2025-03-21
Published by US Federal Register - DEA Telehealth Rules. HealthSignal links to the original document; the summary above is extracted from the source text.